Lixte Biotechnology Holdings Stock Filter Stocks by Fundamentals
LIXT Stock | USD 3.28 0.06 1.86% |
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
Lixte | Shares Owned by Insiders |
Lixte Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Lixte Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lixte Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lixte Biotechnology's value.Shares | Hightower Advisors, Llc | 2023-12-31 | 99.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 7.1 K | Fny Investment Advisers, Llc | 2023-12-31 | 5.5 K | Tower Research Capital Llc | 2023-12-31 | 2.2 K | Wells Fargo & Co | 2023-12-31 | 9.0 | Ubs Group Ag | 2023-12-31 | 3.0 | Ethos Financial Group Llc | 2023-12-31 | 0.0 | Geode Capital Management, Llc | 2023-09-30 | 0.0 | Jpmorgan Chase & Co | 2023-12-31 | 0.0 |
Lixte Fundamentals
Return On Equity | -1.11 | ||||
Return On Asset | -0.64 | ||||
Current Valuation | 6.54 M | ||||
Shares Outstanding | 2.25 M | ||||
Shares Owned By Insiders | 20.48 % | ||||
Shares Owned By Institutions | 5.08 % | ||||
Number Of Shares Shorted | 16.72 K | ||||
Price To Earning | (2.96) X | ||||
Price To Book | 15.55 X | ||||
EBITDA | (5.09 M) | ||||
Net Income | (5.09 M) | ||||
Cash And Equivalents | 7.74 M | ||||
Cash Per Share | 0.47 X | ||||
Debt To Equity | 0.16 % | ||||
Current Ratio | 15.10 X | ||||
Book Value Per Share | 0.22 X | ||||
Cash Flow From Operations | (4.29 M) | ||||
Short Ratio | 0.01 X | ||||
Earnings Per Share | (2.66) X | ||||
Beta | -0.29 | ||||
Market Capitalization | 7.24 M | ||||
Total Asset | 4.31 M | ||||
Retained Earnings | (48.48 M) | ||||
Working Capital | 3.99 M | ||||
Current Asset | 1.38 M | ||||
Current Liabilities | 140 K | ||||
Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lixte Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lixte Biotechnology's short interest history, or implied volatility extrapolated from Lixte Biotechnology options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lixte Biotechnology Piotroski F Score and Lixte Biotechnology Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.